Biomarkers in Clozapine-responding Schizophrenia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Biomarkers in Clozapine-responding Schizophrenia — Stella

Recruiting

Back to Schizophrenia trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Denmark

Mental Health Services Glostrup, Unit for Complicated Schizophrenia, Glostrup Municipality, Denmark

Key details

Phase

Post-approval study

Sponsor

Jimmi Nielsen

Enrollment target

~200 participants

Started

February 2021

Primary completion

December 2029

Age range

18 Years – 64 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov